开颅术后针对胶质母细胞瘤的全肿瘤来源自体细胞靶向免疫治疗
本文通过文献综述评估新诊断胶质母细胞瘤(GBM)的自体细胞疫苗及免疫治疗临床试验现状,指出多数试验为非盲、单组、非随机设计,仅少数涉及生物制剂或双盲随机设计。作者认为其自体细胞产品IGV-001具有独特抗原包容性和抗原不可知性,在已发表的1b期试验中安全性可期且临床疗效出乎意料,并已设计双盲安慰剂对照附加试验,正在进行的2b期试验(NCT04485949)评估IGV-001作为新型免疫治疗平台。
要点
- 文献综述显示神经肿瘤2/3期试验多为非盲(92%)、单组(65%)、非随机(51%),近半为GBM试验。
- 仅10%涉及生物制剂,仅2.2%采用双盲随机试验设计。
- 作者认为其自体细胞产品IGV-001具有独特抗原包容性和抗原不可知性,1b期试验安全性可期且疗效出乎意料。
核心结论
- 作者认为其自体细胞产品具有独特抗原包容性和抗原不可知性,在已发表的1b期试验中安全性可期且临床疗效出乎意料。
- 作者认为IGV-001为历史上难以治疗的新诊断胶质母细胞瘤提供了新型免疫治疗平台,正在进行的2b期试验(NCT04485949)对此进行评估。
研究设计与样本
- 文献综述,评估新诊断胶质母细胞瘤的1期安全性试验以及2期和3期自体来源疫苗的临床结局。
- 作者已设计一项严谨的双盲附加安慰剂对照试验,涉及其可植入生物药物装置。
- 正在进行的2b期试验(NCT04485949)评估IGV-001。
主要发现
- 在一篇涵盖超过3000项神经肿瘤2期和3期临床试验的综述中,大多数试验为非盲(92%)、单组(65%)、非随机(51%),近半为GBM试验。
- 仅10%涉及生物制剂,仅2.2%涉及双盲随机试验设计。
- 作者报告其已发表的1b期试验中该自体细胞产品安全性可期且临床疗效出乎意料。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To date, immunotherapeutic approaches in glioblastoma (GBM) have had limited clinical efficacy as compared to other solid tumors. Here we explore autologous cell treatments that have the potential to circumvent treatment resistance to immunotherapy for GBM. METHODS: We performed literature review and assessed clinical outcomes in phase 1 safety trials as well as phase 2 and 3 autologously-derived vaccines for the treatment of newly-diagnosed GBM. In one recent review of over 3,000 neuro-oncology phase 2 and phase 3 clinical trials, most trials were nonblinded (92%), single group (65%), nonrandomized (51%) and almost half were GBM trials. Only 10% involved a biologic and only 2.2% involved a double-blind randomized trial design. RESULTS: With this comparative literature review we conclude that our autologous cell product is uniquely antigen-inclusive and antigen-agnostic with a promising safety profile as well as unexpected clinical efficacy in our published phase 1b trial. We have since designed a rigorous double-blinded add-on placebo-controlled trial involving our implantable biologic drug device. We conclude that IGV-001 provides a novel immunotherapy platform for historically intransigent ndGBM in this ongoing phase 2b trial (NCT04485949).
引用
- Andrews CE, Zilberberg J, Perez-Olle R, et al. Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy. J Neurooncol. 2023. PMID: 38017340. doi:10.1007/s11060-023-04491-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。